Aura Biosciences, Inc. (NASDAQ:AURA) Given Average Rating of “Buy” by Brokerages

Aura Biosciences, Inc. (NASDAQ:AURA) has received a consensus rating of “Buy” from the seven research firms that are currently covering the firm, Marketbeat Ratings reports. Five analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $23.00.

Several analysts have commented on AURA shares. Cowen reissued a “buy” rating on shares of Aura Biosciences in a report on Friday, October 18th. HC Wainwright restated a “buy” rating and issued a $22.00 price objective on shares of Aura Biosciences in a report on Thursday, November 14th. BTIG Research raised their price target on shares of Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a research note on Friday, October 18th. Evercore ISI raised shares of Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 16th. Finally, Lifesci Capital raised shares of Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 9th.

Aura Biosciences Price Performance

AURA opened at $8.66 on Friday. The firm has a fifty day moving average price of $9.71 and a 200 day moving average price of $8.72. Aura Biosciences has a 1 year low of $6.63 and a 1 year high of $12.38. The stock has a market cap of $432.58 million, a P/E ratio of -5.01 and a beta of 0.27.

Aura Biosciences (NASDAQ:AURA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.02. Equities analysts expect that Aura Biosciences will post -1.66 EPS for the current year.

Insider Activity at Aura Biosciences

In other Aura Biosciences news, CTO Mark Plavsic sold 7,383 shares of the firm’s stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $9.85, for a total transaction of $72,722.55. Following the completion of the sale, the chief technology officer now owns 121,132 shares of the company’s stock, valued at $1,193,150.20. This trade represents a 5.74 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Los Pinos Elisabet De sold 24,992 shares of the business’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $12.04, for a total transaction of $300,903.68. Following the completion of the sale, the insider now owns 329,847 shares in the company, valued at approximately $3,971,357.88. This trade represents a 7.04 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 79,081 shares of company stock valued at $891,353. 5.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Aura Biosciences

Hedge funds and other institutional investors have recently bought and sold shares of the company. American Century Companies Inc. acquired a new stake in Aura Biosciences during the 2nd quarter worth approximately $119,000. SG Americas Securities LLC purchased a new position in Aura Biosciences in the third quarter worth approximately $169,000. Barclays PLC grew its holdings in Aura Biosciences by 256.5% during the 3rd quarter. Barclays PLC now owns 61,010 shares of the company’s stock worth $544,000 after acquiring an additional 43,897 shares in the last quarter. Rhumbline Advisers increased its position in shares of Aura Biosciences by 39.6% in the 2nd quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock valued at $480,000 after purchasing an additional 18,011 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in shares of Aura Biosciences by 14.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 64,452 shares of the company’s stock valued at $487,000 after purchasing an additional 8,194 shares in the last quarter. 96.75% of the stock is currently owned by hedge funds and other institutional investors.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.